Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling Journal Article


Authors: Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S.
Article Title: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
Abstract: The molecular and cellular pathways that support the maintenance and stability of tumor neovessels are not well defined. The efficacy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid regression of specific subsets of tumor neovessels has opened up new avenues of research to identify factors that support tumor neoangiogenesis. Herein, we show that CA4P selectively targeted endothelial cells, but not smooth muscle cells, and induced regression of unstable nascent tumor neovessels by rapidly disrupting the molecular engagement of the endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE-cadherin) in vitro and in vivo in mice. CA4P increases endothelial cell permeability, while inhibiting endothelial cell migration and capillary tube formation predominantly through disruption of VE-cadherin/β-catenin/Akt signaling pathway, thereby leading to rapid vascular collapse and tumor necrosis. Remarkably, stabilization of VE-cadherin signaling in endothelial cells with adenovirus E4 gene or ensheathment with smooth muscle cells confers resistance to CA4P. CA4P synergizes with low and nontoxic doses of neutralizing mAbs to VE-cadherin by blocking assembly of neovessels, thereby inhibiting tumor growth. These data suggest that the microtubule-targeting agent CA4P selectively induces regression of unstable tumor neovessels, in part through disruption of VE-cadherin signaling. Combined treatment with anti-VE-cadherin agents in conjunction with microtubule-disrupting agents provides a novel synergistic strategy to selectively disrupt assembly and induce regression of nascent tumor neovessels, with minimal toxicity and without affecting normal stabilized vasculature.
Keywords: signal transduction; protein kinase b; controlled study; unclassified drug; human cell; drug efficacy; drug potentiation; nonhuman; drug targeting; cell proliferation; animal cell; mouse; animals; mice; cells, cultured; smooth muscle fiber; animal experiment; animal model; antineoplastic agents, phytogenic; in vivo study; cytotoxicity; in vitro study; tumor regression; angiogenesis; neovascularization, pathologic; mice, inbred c57bl; capillary; monoclonal antibody; endothelium cell; endothelial cells; vascular endothelium; endothelium, vascular; combretastatin a4 phosphate; melanoma, experimental; cell migration; tumor vascularization; beta catenin; cadherin; cadherins; virus protein; cell membrane permeability; coculture techniques; adenovirus; vascular endothelial cadherin; capillaries; stilbenes; vascular endothelial cadherin antibody
Journal Title: Journal of Clinical Investigation
Volume: 115
Issue: 11
ISSN: 0021-9738
Publisher: American Society for Clinical Investigation  
Date Published: 2005-11-01
Start Page: 2992
End Page: 3006
Language: English
DOI: 10.1172/jci24586
PUBMED: 16224539
PROVIDER: scopus
PMCID: PMC1253622
DOI/URL:
Notes: --- - "Cited By (since 1996): 106" - "Export Date: 24 October 2012" - "CODEN: JCINA" - "Source: Scopus"
Altmetric Score
MSK Authors